Study
| EST. READ TIME 1 MIN.Access Delayed, Access Denied: Waiting for New Medicines in Canada 2011
This report focuses on new patented medicines because this class of drugs is uniquely affected by public policies that delay access for patients. Because government approval of generic drugs is based on the assumption that generics are copies of new drugs that have previously been approved, there is no substantive delay (observed or expected) before the public has access to generic products; consequently, this class of drugs is not studied in this report.Federal and provincial government policies create unnecessary delays for patients wanting access to new drug treatments. The federal government does not allow patients to use new drugs until Health Canada has reviewed each product?s safety and effectiveness information. The latest data show that in 2009 Health Canada took 472 days on average to approve new drugs, up from 388 days in 2008. Health Canada took longer to approve new drugs than regulators in Europe in all four years studied (2006 to 2009) and longer than the American FDA in five of the last six years studied (2004 to 2009). Relative to other countries, Canadian patients wait too long for government permission to use new drug treatments.
-
Mark Rovere
-
Brett J. Skinner
Brett J. Skinner Dr. Brett J. Skinner was the Fraser Institutes Director of Health Policy Research (2004 to 2012) andwas also the Institutes President and CEO (2010 and 2012). Dr. Skinner has a B.A. from the University of Windsor, an M.A. through joint studies between the University of Windsor and Wayne State University in Detroit (Michigan), and a Ph.D. from the University of Western Ontario, where he has lectured in both the Faculty of Health Sciences and the Department of Political Science. Dr. Skinner has authored or co-authored approximately 50 major original pieces of applied economics and public policy research. In 2003 he was a co-winner of the Atlas Economic Research Foundations Sir Antony Fisher Memorial Award for innovative projects in public policy. Dr. Skinners book, Canadian Health Policy Failures: Whats wrong? Who gets hurt? Why nothing changes, was a finalist for Atlas 2009 Fisher book prize. His research has been published through several think-tanks including the Fraser Institute (Vancouver), the Atlantic Institute for Market Studies (Halifax), the Pacific Research Institute (San Francisco), the American Enterprise Institute (Washington, D.C.) and the Israel National Institute for Health Policy Research (Israel). His work has also been published in several academic journals including Economic Affairs, Pharmacoeconomics and Alimentary Pharmacology & Therapeutics. Dr. Skinner appears and is cited frequently as an expert in the Canadian, American, and global media. He has presented his research at conferences and events around the world, including testifying before the House of Commons Standing Committee on Health in Ottawa, and briefing bi-partisan Congressional policy staff at the U.S. Capitol in Washington, D.C.… Read more